AMLX
Amylyx Pharmaceuticals Inc
28.10$
-3.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5.6% | -18.3% | -101.2% | – | -259.9% | – | – | – | – | – | – | – | |
| – | +79.4% | +1,143.7% | -93.4% | -89.4% | -80.2% | +13,724.4% | -99.4% | +13,981.6% | -99.5% | -9.3% | – | – | |
| – | +1.7% | -128.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +49.5% | -18.5% | -36.8% | -8.2% | +7.8% | -3.4% | +22.4% | -26.7% | +6.3% | +30.8% | -13.9% | – | |
| – | -12.3% | +35.1% | -62.5% | -17.6% | -19.2% | +8.9% | -0.3% | +3.4% | -4.8% | +5.0% | +35.6% | – | |
| – | +23.4% | -2.9% | -52.5% | +68.1% | -46.9% | -60.8% | +172.4% | -62.1% | +125.7% | +20.0% | +4.4% | – | |
| – | -89.7% | -6,414.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -71.1% | -1,930.6% | – | – | – | – | – | – | – | – | – | – | |
| – | +15.0% | -86.1% | – | – | – | – | – | – | – | – | – | – | |
| – | -77.4% | -2,610.9% | – | – | – | – | – | – | – | – | – | – | |
| – | -70.2% | -1,844.7% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.